PET/CT-Directed Free of Therapy for Metastatic RCC Patients With IMDC Favorable or Intermediate Risk

NCT07175480 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Renal Cell Carcinoma (RCC)
Metastatic Renal Cell Carcinoma (mRCC)

Interventions

DRUG: Intermittent PD-1/PD-L1 ICI + VEGFR-TKI

Sponsor

Jinling Hospital, China